Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GALACTUS: Dapagliflozin vs Semaglutide for Inflammation in STEMI
NCT07295223Phase 3Completed
- Sponsor
- Instituto Mexicano del Seguro Social
- Start
- Dec 2025
- Primary completion
- Oct 2026
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in ST-segment elevation myocardial infarction (STEMI) comparing Dapagliflozin with Semaglutide (2 arms). Primary endpoints: High-sensitivity C-reactive protein at 24 weeks and Interleukin 6 at 24 weeks. Started Dec 2025; status: completed.
02
Drugs
dapagliflozinsemaglutide
03
Conditions
ST-segment elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on NCT07295223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07295223.